financetom
Business
financetom
/
Business
/
Honeywell's Mixed Q3: EPS Beats, Misses On Sales, And Lowers FY24 Revenue Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Honeywell's Mixed Q3: EPS Beats, Misses On Sales, And Lowers FY24 Revenue Outlook
Nov 2, 2024 7:44 PM

Honeywell International Inc. ( HON ) shares are trading lower after the company reported third-quarter results and updated FY24 guidance.

Revenue grew 6% year-over-year (organic: +3%) to $9.728 billion, missing the consensus of $9.901 billion.

The sales increase was attributed to strong growth in defense and space, commercial aviation, and building solutions.

Adjusted EPS was $2.58 (+8% Y/Y), beating the consensus of $2.50.

Sales by Segments: Aerospace Technologies $3.912 billion (+12% Y/Y), Industrial Automation $2.50 billion (-5% Y/Y), Building Automation $1.75 billion (+14% Y/Y) and Energy and Sustainability Solutions $1.56 billion (+1% Y/Y).

Operating margin contracted by 180 bps Y/Y to 19.1%, and Segment margin remained flat Y/Y at 23.6% in the quarter.

Operating cash flow stood at $2.00 billion and, free cash flow was $1.72 billion. Honeywell ( HON ) held cash and equivalents of about $10.6 billion as of September 30, 2024.

The company deployed $3.1 billion to M&A, dividends, and capital expenditure.

FY24 Outlook: The company lowered sales guidance to $38.6 billion – $38.8 billion (from $39.1 billion – $39.7 billion prior) versus the consensus of $39.20 billion.

Honeywell ( HON ) tightened adjusted EPS guidance to $10.15 – $10.25 (from $10.05 – $10.25) versus the estimate of $10.13.

Also, Honeywell ( HON ) revised the outlook for segment margin to 23.4% – 23.5% (from 23.3% – 23.5% prior), with segment margin contraction of 10 bps to flat.

The company now expects an operating cash flow of $6.2 billion – $6.5 billion and a free cash flow of $5.1 billion – $5.4 billion.

Honeywell ( HON ) chairman and CEO Vimal Kapur said, “Our Accelerator operating system and culture of execution enabled us to grow segment profit by 6% in spite of transitory sales headwinds. We continue to see healthy order rates and sequential growth in our backlog, even excluding the impact of acquisitions closed in the quarter, giving us confidence in our ability to achieve our long-term targets.”

“We have made significant progress this year on the simplification and optimization of the Honeywell ( HON ) portfolio with the announcement of our plans to spin off Advanced Materials and exit our PPE business, as well as the closing of four strategic acquisitions.”

Investors can gain exposure to the stock via Themes Transatlantic Defense ETF ( NATO ) and Invesco Aerospace & Defense ETF ( PPA ) .

Price Action: HON shares are down 1.98% at $215.99 premarket at the last check Thursday.

Read Next:

Honeywell Expands Qualcomm Partnership: AI And Connectivity To Supercharge Energy Industry Operations

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
May 9, 2024
May 9 (Reuters) - Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure. Net sales in its branded drugs unit, which makes up two-thirds of the company's total revenues, also fell 4.5% to $2.31 billion. Viatris ( VTRS ), formed by...
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
May 9, 2024
08:26 AM EDT, 05/09/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported a Q1 non-GAAP net loss Thursday of $0.02 per diluted share, compared with a loss of $0.06 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.03. Net product sales for the quarter ended March 31 were $110.4 million, compared with $86.3 million a...
Tower Semiconductor's Q1 Adjusted Earnings, Revenue Fall; Q2 Sales Outlook Issued
Tower Semiconductor's Q1 Adjusted Earnings, Revenue Fall; Q2 Sales Outlook Issued
May 9, 2024
08:24 AM EDT, 05/09/2024 (MT Newswires) -- Tower Semiconductor ( TSEM ) reported Q1 adjusted earnings Thursday of $0.46 per diluted share, down from $0.61 a year earlier. Four analysts polled by Capital IQ expected $0.39. Revenue for the quarter ended March 31 was $327.2 million, compared with $355.6 million a year earlier. Four analysts surveyed by Capital IQ expected...
Novo Nordisk ties up with Metaphore to develop new obesity drugs
Novo Nordisk ties up with Metaphore to develop new obesity drugs
May 9, 2024
May 9 (Reuters) - Novo Nordisk signed a research tie-up with U.S. biotech firm Metaphore on Thursday to develop next-generation obesity drugs. WHY IT'S IMPORTANT Danish drugmaker Novo is trying to expand beyond its blockbuster obesity drug Wegovy with at least eight other treatments in its R&D pipeline for the condition. The collaboration will use Metaphore's tech platform to develop...
Copyright 2023-2026 - www.financetom.com All Rights Reserved